medical advisory board
Dr. Julia Glade Bender
Dr. Julia Glade Bender is a Full Member (Professor), Vice Chairman for Pediatric Clinical Research and co- Medical Director of the Lisa and Scott Stuart Center for Adolescent and Young Adult (AYA) Cancer at Memorial Sloan Kettering Cancer Center (MSK). A graduate of Yale University and the University of Pennsylvania School of Medicine, Dr. Glade Bender completed her pediatric residency at the Mount Sinai Hospital and her pediatric hematology-oncology fellowship at MSK. Her clinical research has focused on the development of targeted agents for children and AYA with advanced solid tumors and the identification of biomarkers predictive of response.
-
Dr. Glade Bender has provided broad scientific leadership for early phase clinical trial development sponsored by the National Cancer Institute (NCI), the Children’s Oncology Group (COG), as well as smaller disease-oriented consortia and pharmaceutical industry chairing or vice chairing more than 15 national trials, including as Vice-Chair for the most recent phase 3 trial for patients with metastatic Ewing sarcoma. She has also proudly served as the developmental therapeutics (new agent) liaison to the COG Bone Tumor Committee for more than a decade.
At MSK kids, Dr. Glade Bender’s clinical practice revolves around children and AYA with sarcoma and rare solid tumors. Her passion is to accelerate the introduction of promising targeted agents into the upfront treatment of diseases like Ewing sarcoma, where no progress has been made in 4 decades, to improve patient outcomes with less toxicity, and while doing so, to train the next generation of clinician scientists.
Dr. Noah Federman
Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman also holds the Jonathan and Nancy Glaser Endowed Chair in Pediatric Sarcomas. He specializes in treating children, adolescents and young adults with these aggressive cancers. He runs an incredibly comprehensive and & multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists.
-
Dr. Federman also specializes in conducting clinical trials and leads an experienced clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.
Dr. Federman is currently the Medical Director of the UCLA Clinical and Translational Research Center overseeing close to four hundred clinical trials. In addition, he serves as Vice-Chair of the Clinical and Translational Science Institute’s (CTSI) Scientific Rationale Committee and is Chair of the CTSI Data Safety Monitoring Board. In these roles, he ensures that clinical research is of the highest quality and being performed with utmost safety at UCLA. He is also the Medical Director of the UCLA CTSI’s Research Associates Program (RAP) which provides undergraduate UCLA students with the opportunity to gain exposure to hospital-based medicine as well as clinical research in an academic setting.
Dr. Patrick Grohar
Dr. Patrick Grohar is the Russell G. Adderley Professor of Pediatric Oncology and Professor of Pediatrics at University of Michigan Medical School. Dr. Patrick Grohar did his undergraduate degree in chemistry at Villanova University. He subsequently attended Wayne State University where he earned a PhD in chemistry at studying post-transcriptional nucleic acid modifications in the lab of Christine Chow. He went on to attend Wayne State for medical school where he graduated with distinction in biomedical research. Dr Grohar completed residency in pediatrics at Johns Hopkins where he trained on the alternative research track. He completed fellowship in the joint program between Johns Hopkins and the Pediatric Oncology Branch of the National Cancer Institute, serving as chief fellow in his final year.
-
He rose through the ranks with faculty stints at Vanderbilt, the Van Andel Institute and then spent the last five years at Children’s Hospital of Philadelphia and UPenn. At CHOP he served as the director of translational research. Most recently, he was recruited to the University of Michigan as Professor and awarded the endowed Adderley Professor of Pediatric Oncology in the Department of Pediatrics.
He was awarded a prestigious SOAR (Support for Outstanding Research) award from the medical school.
The focus of Dr. Grohar’s work is on bench to bedside research targeting challenging drug targets for Ewing sarcoma and related tumors. He focuses on a mechanistic pharmacology approach that leverages advanced to technology to advance small molecule therapies to the clinic. Most recently, he led a study called SARC037, based on work in his laboratory, that was presented orally at the Annual Meeting of the American Society of Clinical Oncology. He holds leadership positions nationally in the COG as co-chair of sarcoma biology, vice-chair of bone tumor and chair of Ewing sarcoma. He has been awarded numerous grants and currently has an R01, U01, SU2C, V-foundation and St. Baldrick grant. He has published in excellent journals is the lead author on the textbook chapter of Ewing sarcoma (Pizzo and Poplack).
medical advisory board
Dr. Julia Glade Bender
-
Dr. Julia Glade Bender is a Full Member (Professor), Vice Chairman for Pediatric Clinical Research and co- Medical Director of the Lisa and Scott Stuart Center for Adolescent and Young Adult (AYA) Cancer at Memorial Sloan Kettering Cancer Center (MSK). A graduate of Yale University and the University of Pennsylvania School of Medicine, Dr. Glade Bender completed her pediatric residency at the Mount Sinai Hospital and her pediatric hematology-oncology fellowship at MSK. Her clinical research has focused on the development of targeted agents for children and AYA with advanced solid tumors and the identification of biomarkers predictive of response. She has provided broad scientific leadership for early phase clinical trial development sponsored by the National Cancer Institute (NCI), the Children’s Oncology Group (COG), as well as smaller disease-oriented consortia and pharmaceutical industry chairing or vice chairing more than 15 national trials, including as Vice-Chair for the most recent phase 3 trial for patients with metastatic Ewing sarcoma. She has also proudly served as the developmental therapeutics (new agent) liaison to the COG Bone Tumor Committee for more than a decade.
At MSK kids, Dr. Glade Bender’s clinical practice revolves around children and AYA with sarcoma and rare solid tumors. Her passion is to accelerate the introduction of promising targeted agents into the upfront treatment of diseases like Ewing sarcoma, where no progress has been made in 4 decades, to improve patient outcomes with less toxicity, and while doing so, to train the next generation of clinician scientists.
Dr. Patrick Grohar
-
Dr. Patrick Grohar is the Russell G. Adderley Professor of Pediatric Oncology and Professor of Pediatrics at University of Michigan Medical School. Dr. Patrick Grohar did his undergraduate degree in chemistry at Villanova University. He subsequently attended Wayne State University where he earned a PhD in chemistry at studying post-transcriptional nucleic acid modifications in the lab of Christine Chow. He went on to attend Wayne State for medical school where he graduated with distinction in biomedical research. Dr Grohar completed residency in pediatrics at Johns Hopkins where he trained on the alternative research track. He completed fellowship in the joint program between Johns Hopkins and the Pediatric Oncology Branch of the National Cancer Institute, serving as chief fellow in his final year.
He rose through the ranks with faculty stints at Vanderbilt, the Van Andel Institute and then spent the last five years at Children’s Hospital of Philadelphia and UPenn. At CHOP he served as the director of translational research. Most recently, he was recruited to the University of Michigan as Professor and awarded the endowed Adderley Professor of Pediatric Oncology in the Department of Pediatrics.
He was awarded a prestigious SOAR (Support for Outstanding Research) award from the medical school.
The focus of Dr. Grohar’s work is on bench to bedside research targeting challenging drug targets for Ewing sarcoma and related tumors. He focuses on a mechanistic pharmacology approach that leverages advanced to technology to advance small molecule therapies to the clinic. Most recently, he led a study called SARC037, based on work in his laboratory, that was presented orally at the Annual Meeting of the American Society of Clinical Oncology. He holds leadership positions nationally in the COG as co-chair of sarcoma biology, vice-chair of bone tumor and chair of Ewing sarcoma. He has been awarded numerous grants and currently has an R01, U01, SU2C, V-foundation and St. Baldrick grant. He has published in excellent journals is the lead author on the textbook chapter of Ewing sarcoma (Pizzo and Poplack).
Dr. Noah Federman
-
Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman also holds the Jonathan and Nancy Glaser Endowed Chair in Pediatric Sarcomas. He specializes in treating children, adolescents and young adults with these aggressive cancers. He runs an incredibly comprehensive and & multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. Dr. Federman also specializes in conducting clinical trials and leads an experienced clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.
Dr. Federman is currently the Medical Director of the UCLA Clinical and Translational Research Center overseeing close to four hundred clinical trials. In addition, he serves as Vice-Chair of the Clinical and Translational Science Institute’s (CTSI) Scientific Rationale Committee and is Chair of the CTSI Data Safety Monitoring Board. In these roles, he ensures that clinical research is of the highest quality and being performed with utmost safety at UCLA. He is also the Medical Director of the UCLA CTSI’s Research Associates Program (RAP) which provides undergraduate UCLA students with the opportunity to gain exposure to hospital-based medicine as well as clinical research in an academic setting.